Arsanis (ASNS) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Arsanis (NASDAQ:ASNS) issued its quarterly earnings results on Friday. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.02), MarketWatch Earnings reports.

Shares of NASDAQ:ASNS traded down $0.06 during midday trading on Friday, hitting $1.37. The stock had a trading volume of 857,225 shares, compared to its average volume of 198,372. Arsanis has a 12 month low of $1.25 and a 12 month high of $28.69. The company has a current ratio of 5.54, a quick ratio of 5.54 and a debt-to-equity ratio of 0.20. The stock has a market capitalization of $19.75 million and a PE ratio of -0.08.

ASNS has been the subject of several research reports. Zacks Investment Research cut shares of Arsanis from a “buy” rating to a “hold” rating in a research note on Monday, October 15th. ValuEngine raised shares of Arsanis from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. Finally, Piper Jaffray Companies decreased their price target on shares of Arsanis to $2.50 and set a “neutral” rating for the company in a research note on Monday, August 13th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $14.88.

ILLEGAL ACTIVITY WARNING: “Arsanis (ASNS) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.com-unik.info/2018/11/10/arsanis-asns-posts-quarterly-earnings-results-misses-estimates-by-0-02-eps.html.

About Arsanis

Arsanis, Inc, a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases. Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients.

Featured Story: Investing strategies using the yield curve

Receive News & Ratings for Arsanis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arsanis and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit